Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) CD Antigen Cancer Therapy Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global CD Antigen Cancer Therapy Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Monoclonal Antibodies
      • 1.3.3 Antibody-Drug-Conjugates
      • 1.3.4 Tri-Functional and Bi-Specific T-Cell Engager Antibodies
      • 1.3.5 Other
    • 1.4 Market Segment by Application
      • 1.4.1 Global CD Antigen Cancer Therapy Market Share by Application (2019-2025)
      • 1.4.2 Hospitals
      • 1.4.3 Clinics
      • 1.4.4 Other
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global CD Antigen Cancer Therapy Market Size
      • 2.1.1 Global CD Antigen Cancer Therapy Revenue 2014-2025
      • 2.1.2 Global CD Antigen Cancer Therapy Sales 2014-2025
    • 2.2 CD Antigen Cancer Therapy Growth Rate by Regions
      • 2.2.1 Global CD Antigen Cancer Therapy Sales by Regions 2014-2019
      • 2.2.2 Global CD Antigen Cancer Therapy Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 CD Antigen Cancer Therapy Sales by Manufacturers
      • 3.1.1 CD Antigen Cancer Therapy Sales by Manufacturers 2014-2019
      • 3.1.2 CD Antigen Cancer Therapy Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 CD Antigen Cancer Therapy Revenue by Manufacturers (2014-2019)
      • 3.2.2 CD Antigen Cancer Therapy Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global CD Antigen Cancer Therapy Market Concentration Ratio (CR5 and HHI)
    • 3.3 CD Antigen Cancer Therapy Price by Manufacturers
    • 3.4 Key Manufacturers CD Antigen Cancer Therapy Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into CD Antigen Cancer Therapy Market
    • 3.6 Key Manufacturers CD Antigen Cancer Therapy Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Monoclonal Antibodies Sales and Revenue (2014-2019)
      • 4.1.2 Antibody-Drug-Conjugates Sales and Revenue (2014-2019)
      • 4.1.3 Tri-Functional and Bi-Specific T-Cell Engager Antibodies Sales and Revenue (2014-2019)
      • 4.1.4 Other Sales and Revenue (2014-2019)
    • 4.2 Global CD Antigen Cancer Therapy Sales Market Share by Type
    • 4.3 Global CD Antigen Cancer Therapy Revenue Market Share by Type
    • 4.4 CD Antigen Cancer Therapy Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global CD Antigen Cancer Therapy Sales by Application

    6 United States

    • 6.1 United States CD Antigen Cancer Therapy Breakdown Data by Company
    • 6.2 United States CD Antigen Cancer Therapy Breakdown Data by Type
    • 6.3 United States CD Antigen Cancer Therapy Breakdown Data by Application

    7 European Union

    • 7.1 European Union CD Antigen Cancer Therapy Breakdown Data by Company
    • 7.2 European Union CD Antigen Cancer Therapy Breakdown Data by Type
    • 7.3 European Union CD Antigen Cancer Therapy Breakdown Data by Application

    8 China

    • 8.1 China CD Antigen Cancer Therapy Breakdown Data by Company
    • 8.2 China CD Antigen Cancer Therapy Breakdown Data by Type
    • 8.3 China CD Antigen Cancer Therapy Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World CD Antigen Cancer Therapy Breakdown Data by Company
    • 9.2 Rest of World CD Antigen Cancer Therapy Breakdown Data by Type
    • 9.3 Rest of World CD Antigen Cancer Therapy Breakdown Data by Application
    • 9.4 Rest of World CD Antigen Cancer Therapy Breakdown Data by Countries
      • 9.4.1 Rest of World CD Antigen Cancer Therapy Sales by Countries
      • 9.4.2 Rest of World CD Antigen Cancer Therapy Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 AryoGen Biopharma
      • 10.1.1 AryoGen Biopharma Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of CD Antigen Cancer Therapy
      • 10.1.4 CD Antigen Cancer Therapy Product Introduction
      • 10.1.5 AryoGen Biopharma Recent Development
    • 10.2 Biocad
      • 10.2.1 Biocad Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of CD Antigen Cancer Therapy
      • 10.2.4 CD Antigen Cancer Therapy Product Introduction
      • 10.2.5 Biocad Recent Development
    • 10.3 Biogen Idec
      • 10.3.1 Biogen Idec Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of CD Antigen Cancer Therapy
      • 10.3.4 CD Antigen Cancer Therapy Product Introduction
      • 10.3.5 Biogen Idec Recent Development
    • 10.4 Celltrion
      • 10.4.1 Celltrion Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of CD Antigen Cancer Therapy
      • 10.4.4 CD Antigen Cancer Therapy Product Introduction
      • 10.4.5 Celltrion Recent Development
    • 10.5 Genentech
      • 10.5.1 Genentech Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of CD Antigen Cancer Therapy
      • 10.5.4 CD Antigen Cancer Therapy Product Introduction
      • 10.5.5 Genentech Recent Development
    • 10.6 Genmab
      • 10.6.1 Genmab Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of CD Antigen Cancer Therapy
      • 10.6.4 CD Antigen Cancer Therapy Product Introduction
      • 10.6.5 Genmab Recent Development
    • 10.7 GLYCART Biotechnology
      • 10.7.1 GLYCART Biotechnology Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of CD Antigen Cancer Therapy
      • 10.7.4 CD Antigen Cancer Therapy Product Introduction
      • 10.7.5 GLYCART Biotechnology Recent Development
    • 10.8 Hetero Drugs
      • 10.8.1 Hetero Drugs Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of CD Antigen Cancer Therapy
      • 10.8.4 CD Antigen Cancer Therapy Product Introduction
      • 10.8.5 Hetero Drugs Recent Development
    • 10.9 mAbxience
      • 10.9.1 mAbxience Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of CD Antigen Cancer Therapy
      • 10.9.4 CD Antigen Cancer Therapy Product Introduction
      • 10.9.5 mAbxience Recent Development
    • 10.10 MedImmune
      • 10.10.1 MedImmune Company Details
      • 10.10.2 Company Description and Business Overview
      • 10.10.3 Sales, Revenue and Market Share of CD Antigen Cancer Therapy
      • 10.10.4 CD Antigen Cancer Therapy Product Introduction
      • 10.10.5 MedImmune Recent Development
    • 10.11 Merck
    • 10.12 Sandoz
    • 10.13 UCB

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 CD Antigen Cancer Therapy Sales Channels
      • 11.2.2 CD Antigen Cancer Therapy Distributors
    • 11.3 CD Antigen Cancer Therapy Customers

    12 Market Forecast

    • 12.1 Global CD Antigen Cancer Therapy Sales and Revenue Forecast 2019-2025
    • 12.2 Global CD Antigen Cancer Therapy Sales Forecast by Type
    • 12.3 Global CD Antigen Cancer Therapy Sales Forecast by Application
    • 12.4 CD Antigen Cancer Therapy Forecast by Regions
      • 12.4.1 Global CD Antigen Cancer Therapy Sales Forecast by Regions 2019-2025
      • 12.4.2 Global CD Antigen Cancer Therapy Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      In 2019, the market size of CD Antigen Cancer Therapy is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for CD Antigen Cancer Therapy.

      This report studies the global market size of CD Antigen Cancer Therapy, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the CD Antigen Cancer Therapy sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      AryoGen Biopharma
      Biocad
      Biogen Idec
      Celltrion
      Genentech
      Genmab
      GLYCART Biotechnology
      Hetero Drugs
      mAbxience
      MedImmune
      Merck
      Sandoz
      UCB

      Market Segment by Product Type
      Monoclonal Antibodies
      Antibody-Drug-Conjugates
      Tri-Functional and Bi-Specific T-Cell Engager Antibodies
      Other

      Market Segment by Application
      Hospitals
      Clinics
      Other

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the CD Antigen Cancer Therapy status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key CD Antigen Cancer Therapy manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of CD Antigen Cancer Therapy are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now